Oral administration of a bioactive compound from neem — a medicinal plant native to the Indian subcontinent — may significantly suppress development of prostate cancer, a new study led by an Indian or
Oral administration of a bioactive compound from neem — a medicinal plant native to the Indian subcontinent — may significantly suppress development of prostate cancer, a new study led by an Indian origin scientist has claimed. Consumption of nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant over 12 weeks shows reduction of prostate tumour size by up to 70 per cent and decrease in tumour metastasis by up to 50 per cent, researchers said.
Prostate cancer is one of the most commonly diagnosed cancers worldwide, said researchers led by Associate Professor Gautam Sethi from the National University of Singapore (NUS).
However, currently available therapies for metastatic prostate cancer are only marginally effective. Hence, there is a need for more novel treatment alternatives and options.
“Although the diverse anti-cancer effects of nimbolide have been reported in different cancer types, its potential effects on prostate cancer initiation and progression have not been demonstrated in scientific studies,” said Sethi.
